Compare OSW & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | PHVS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Bahamas | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2019 | 2020 |
| Metric | OSW | PHVS |
|---|---|---|
| Price | $28.20 | $34.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $27.00 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 802.3K | 331.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $961,001,000.00 | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $129.81 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $19.06 | $16.72 |
| 52 Week High | $29.25 | $35.33 |
| Indicator | OSW | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 64.43 |
| Support Level | $19.70 | $24.73 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.16 | 1.61 |
| MACD | 0.27 | 0.19 |
| Stochastic Oscillator | 82.98 | 71.94 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.